Prostate Cancer Coverage from Every Angle
Editor:
Sandy Srinivas, MD
Advertisement
Advertisement

Videos

Daniel P. Petrylak, MD, on Understanding ARV-110, an Oral PROTAC Degrader for Prostate Cancer Treatment

Michael J. Morris, MD, on PSMA-Targeted Imaging for Prostate Cancer: CONDOR Trial

Neal D. Shore, MD, on a Possible New Standard of Care in Oral Therapy for Advanced Prostate Cancer

Rana R. McKay, MD: Which Patients Might Benefit From Neoadjuvant Androgen Deprivation Before Radical Prostatectomy?

Amir Goldkorn, MD, on Challenges of Integrating a Prostate Cancer Prognostic Marker Into Standard Practice

Michael S. Hofman, MBBS, on LuPSMA vs Cabazitaxel: Clinical Implications of the ANZUP 1603 Prostate Cancer Trial

Christopher Sweeney, MBBS, on Prostate Cancer: IMbassador250 Trial on Atezolizumab and Enzalutamide

Julie N. Graff, MD, on Pembrolizumab Plus Enzalutamide for Enzalutamide-Resistant Metastatic Castration-Resistant Disease

Hannah L. Rush, MBChB, on Self-Reported Quality of Life in the STAMPEDE Trial

Karim Fizazi, MD, PhD, on Chemotherapy vs Endocrine Therapy: Patient-Reported Outcomes

David P. Dearnaley, MD, on Helping Patients Tolerate Radiation Therapies for Prostate Cancer

Maha H.A. Hussain, MD, on Managing Nausea and Fatigue in Men Treated for Prostate Cancer

Nicholas D. James, PhD, MBBS, on Frequency of Imaging Studies in Patients Treated With Enzalutamide

Maha H.A. Hussain, MD, on Castration-Resistant Prostate Cancer: Future Directions for PARP Inhibitors

Ryan Phillips, MD, PhD, on Observation or Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer?

Daniel E. Spratt, MD, on Pros and Cons of Antiandrogen Treatment in Prostate Cancer

Michael J. Morris, MD, on the Alliance Trial: Clinical Implications of Combination Therapy for Prostate Cancer

Kim N. Chi, MD, on Adding Apalutamide to Androgen-Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer

Karim Fizazi, MD, PhD, on Darolutamide Treatment in Prostate Cancer: Helping Patients Assess Benefits vs Risks

Christopher Sweeney, MBBS, on Adding Enzalutamide to the Treatment Landscape for Metastatic Hormone-Sensitive Prostate Cancer

James L. Mohler, MD, on Prostate Cancer: An Update on Treatment Recommendations

Sumit K. Subudhi, MD, PhD, on Managing Apalutamide Toxicities in Prostate Cancer

Howard I. Scher, MD, on Managing Enzalutamide Toxicities in Prostate Cancer

Sumit K. Subudhi, MD, PhD, on Monitoring the Progress of Prostate Cancer Treated With Apalutamide

Jeremy Warner, MD, on Patient Navigation: The Proactive Approach

Nicholas D. James, PhD, MBBS, on Radiotherapy and Abiraterone in Prostate Cancer

Charles von Gunten, MD, PhD, on Opioids for Managing Cancer Pain

Carmel Jo Pezaro, MB, ChB, on Prostate Cancer and PARP Inhibitors

James L. Mohler, MD, on Prostate Cancer: Updated NCCN Recommendations

Eric Roeland, MD, on Prophylactic Strategies for Highly Emetogenic Chemotherapy

Betty R. Ferrell, PhD, on the Impact of Immunotherapy on Patients' Well-Being

Simron Singh, MD, MPH, on Patient-Centered Care: Measuring Experience

Neeraj K. Arora, PhD, on Patient-Centered Care in Clinical Practice

Peter R. Carroll, MD, MPH, on Prostate Cancer: Risks of Early Detection

Maha Hussain, MD, and Eric J. Small, MD, on Prostate Cancer and Antiandrogens: Results From the PROSPER and SPARTAN Trials

The JNCCN Spotlight

Copyright © 2020 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.